Естонија - Естонски - Ravimiamet

norbrook laboratories (ireland) limited - propofool - süsteemulsioon - 10mg 1ml 50ml 1tk

Естонија - Естонски - Ravimiamet

baxter holding b.v. - propofool - süste-/infusiooniemulsioon - 10mg 1ml 100ml 1tk; 10mg 1ml 20ml 5tk; 10mg 1ml 10ml 1tk

Естонија - Естонски - Ravimiamet

guerbet - gadoteerhape - süstelahus - 0,5mmol 1ml 60ml 1tk

Естонија - Естонски - Ravimiamet

csl behring gmbh - viii hüübimisfaktor - süste-/infusioonilahuse pulber ja lahusti - 500rÜ 1tk

Естонија - Естонски - Ravimiamet

csl behring gmbh - viii hüübimisfaktor - süste-/infusioonilahuse pulber ja lahusti - 250rÜ 1tk

Естонија - Естонски - Ravimiamet

csl behring gmbh - viii hüübimisfaktor - süste-/infusioonilahuse pulber ja lahusti - 2000rÜ 1tk

Естонија - Естонски - Ravimiamet

csl behring gmbh - viii hüübimisfaktor - süste-/infusioonilahuse pulber ja lahusti - 1000rÜ 1tk

Естонија - Естонски - Ravimiamet

norbrook laboratories (ireland) limited - tulatromütsiin - süstelahus - 100mg 1ml 1000ml 1tk; 100mg 1ml 50ml 1tk; 100mg 1ml 500ml 1tk

Естонија - Естонски - Ravimiamet

bimeda animal health limited - tulatromütsiin - süstelahus - 100mg 1ml 250ml 1tk; 100mg 1ml 500ml 1tk

Европска Унија - Естонски - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.